Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting...